Endo Pharmaceuticals Holdings Beats on EPS, but GAAP Results Lag

Before you go, we thought you'd like these...
Before you go close icon

Endo Pharmaceuticals Holdings (NAS: ENDP) reported earnings on Feb. 24. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Endo Pharmaceuticals Holdings met expectations on revenues and beat expectations on earnings per share.

Compared with the prior-year quarter, revenue increased significantly and GAAP earnings per share contracted significantly.

Margins contracted across the board.

Revenue details
Endo Pharmaceuticals Holdings booked revenue of $803.4 million. The 19 analysts polled by S&P Capital IQ hoped for a top line of $804.2 million on the same basis. GAAP reported sales were 57% higher than the prior-year quarter's $511.2 million.

anImage

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Non-GAAP EPS came in at $1.40. The 22 earnings estimates compiled by S&P Capital IQ predicted $1.32 per share on the same basis. GAAP EPS of $0.30 for Q4 were 61% lower than the prior-year quarter's $0.77 per share.

anImage

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 63.3%, 350 basis points worse than the prior-year quarter. Operating margin was 26.2%, 490 basis points worse than the prior-year quarter. Net margin was 4.6%, 1,360 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $743.2 million. On the bottom line, the average EPS estimate is $1.10.

Next year's average estimate for revenue is $3.22 billion. The average EPS estimate is $5.44.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 434 members out of 454 rating the stock outperform, and 20 members rating it underperform. Among 164 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 163 give Endo Pharmaceuticals Holdings a green thumbs-up, and one give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Endo Pharmaceuticals Holdings is outperform, with an average price target of $44.78.

The drug and health-care investing landscape is littered with also-rans and a few major winners. Is Endo Pharmaceuticals Holdings the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Get instant access to this free report.

At the time this article was published

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners